Since the first Nrf2 inducer DMF was approved for the treatment of multiple sclerosis, the discovery of KEAP1-NRF2 PPI inhibitors has become a very interesting alternative to the development of Nrf2 inducers with potentially safer clinical applications (Crisman et al., 2023). This evidence concerns the gene KEAP1 and multiple sclerosis.